A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 14, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions
Thyroid Cancer
Interventions
DRUG

Dabrafenib 75 MG

Refer arm description

DRUG

Trametinib 2 MG

Refer arm description

Trial Locations (9)

3084

RECRUITING

Austin Health, Heidelberg

3128

NOT_YET_RECRUITING

Eastern Health, Box Hill

3168

RECRUITING

Monash Health, Clayton

4029

RECRUITING

Royal Brisbane and Women's Hospital, Brisbane

Unknown

RECRUITING

Royal North Shore Hospital, Sydney

RECRUITING

Royal Adelaide Hsopital, Adelaide

NOT_YET_RECRUITING

Alfred Hospital, Prahran

RECRUITING

Sir Charles Gairdner Hospital, Perth

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

All Listed Sponsors
collaborator

Royal North Shore Hospital

OTHER

collaborator

Austin Health

OTHER_GOV

collaborator

Sir Charles Gairdner Hospital

OTHER

collaborator

Monash Health

OTHER

collaborator

Peter MacCallum Cancer Centre, Australia

OTHER

collaborator

Royal Brisbane and Women's Hospital

OTHER_GOV

collaborator

Eastern Health

OTHER

collaborator

The Alfred

OTHER

collaborator

Royal Adelaide Hospital

OTHER

lead

Olivia Newton-John Cancer Research Institute

OTHER

NCT05182931 - A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) | Biotech Hunter | Biotech Hunter